Trygg Pharma, Inc.   Report issue

For profit Phase 3
Founded: Oslo Norway (2009)
Status: Defunct (2015)

Organization Overview

First Clinical Trial
2010
NCT01229566
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2010

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

omega-3 ethyl esters (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hypertriglyceridemia (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1